Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s stock price traded down 9.1% on Tuesday . The company traded as low as $0.35 and last traded at $0.35. 344,384 shares changed hands during trading, an increase of 68% from the average session volume of 205,318 shares. The stock had previously closed at $0.39. AIM ImmunoTech […]
AIM ImmunoTech Inc. (NYSE: AIM) shares poked ahead to begin the first full week of May, having announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed ...
OCALA, Fla., May 06, 2024 -- AIM ImmunoTech Inc. today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® , AIM’s dsRNA product candidate being...
Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have...